AzTrials
AzTrials

Pelvic Organ ProlapseEVeRLASTNCT04329715

Expedited Versus Restrictive: Limitations on Activity Following Surgical Treatment of Prolapse

A study testing Expedited postoperative activity instructions and Standard postoperative activity restructions in people with Pelvic Organ Prolapse, run by Duke University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of the EVeRLAST study is to determine whether expedited resumption of postoperative activity levels is non-inferior to standard activity restrictions with respect to short-term anatomic prolapse outcomes. Read more about this study

Who is it for?
Any age, women onlyHealthy volunteers can take part
Conditions the study is for
Pelvic Organ Prolapse
What is being tested?
Expedited postoperative activity instructions and Standard postoperative activity restructions
Could I receive a placebo?
No, everyone receives an active treatment
How many people
123 participants
Where
1 siteUnited States
Study dates
1 Jul 2020to 15 Feb 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Stage II-IV pelvic organ prolapse
  • Bothersome bulge symptoms
  • At least 725 MET-minutes/week on International Physical Activity Questionnaire Short Form
  • English-speaking
  • Undergoing treatment of prolapse
  • Surgery occurring at least 7 days from date of randomization (to allow for collection of at least 7 days of preoperative accelerometer data)
  • Able and willing to follow up at 3 months for in-office exam

Who cannot join

  • Enrollment in another research study of pelvic organ prolapse
  • Concomitant non-urogynecologic surgery
  • Planned further surgery in the next 3 months or anticipated treatment which would result in prolonged inactivity (such as a cancer diagnosis) 3 months postoperatively

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Duke University Medical Center

    Durham, North Carolina, 27710

Other trials in United States

About this study

The objective of the EVeRLAST study is to determine whether expedited resumption of postoperative activity levels is non-inferior to standard activity restrictions with respect to short-term anatomic prolapse outcomes. We hypothesize that immediate resumption of physical activities as tolerated will result in noninferior surgical outcomes following prolapse surgery when compared to standard postoperative activity restrictions.

Participants will be enrolled and randomized at their preoperative clinic visit to one of two treatment arms:

Read more

Arm 1: Standard instructions (no heavy lifting over 10lbs for 6 weeks; return to work at 4 weeks for sedentary work and 6 weeks for manual labor) Arm 2: Liberal instructions (no restrictions; resume activities and work as soon as able)

We will also collect subjective and objective measures of pre- and postoperative physical activity, through the use of patient-reported physical activity assessments and wrist-worn accelerometers. Accelerometer data will be collected at the preoperative, 2-week-postoperative, and 6-week-postoperative time points. Accelerometer data will also be used to calculate time to resumption of normal activities, defined as time at which a patient resumes greater than 90% of her baseline preoperative level of physical activity. We will additionally be collecting data on relevant patient-reported outcomes of pelvic floor symptom severity, health-related quality of life measures, postoperative pain, time to return to work (where relevant), and patient global impression of improvement. Postoperative anatomic assessments will be performed at 6 weeks and 3 months postoperatively by blinded study personnel

Read the detailed description

Specific aim 1: Determine if liberal (ad lib) resumption of postoperative activity levels is non-inferior to standard restrictions with regards to short-term anatomic and symptomatic outcome, as measured by maximum pelvic organ prolapse support loss ('SLmax') and the Pelvic Organ Prolapse Distress Inventory (POPDI) at 3 months. (Co-primary outcome)

Specific aim 2: Compare postoperative "Recovery Time" and physical function between women instructed to resume their activity levels ad lib versus women instructed to restrict activity levels. "Recovery Time," defined as the postoperative day at which the patient resumes 90% of her baseline activity levels will be objectively measured using the Actigraph accelerometer.8 ,9 Physical function will be measured with the 6-minute walk, chair stand tests, and through patient-reported outcome measures. (exploratory outcome)

Specific aim 3: Compare timing of return-to-work and health-related QOL in women instructed to resume activity levels and return to work ad lib versus restrict their activity levels (exploratory outcome)

Eligible participants will first be briefly explained regarding the research study. If interested, will then complete the informed consent process. She will first be asked to complete the International Physical Activity Short Form to confirm study eligibility. For study eligibility, participants must at least report a baseline of 725 MET-minutes per week of physical activity according to the IPAQ-SF, which is consistent with the lowest quartile of activity among elderly women. If she reports greater than 725 MET-minutes per week of physical activity, she will undergo the remainder of baseline assessments. If she reports less than 725 MET-minutes per week of physical activity, she will be explained that she does not meet the activity level criteria for completion of the study at this time. She will then be asked to complete a series of baseline questionnaires (demographics, past medical history, POPDI, AAS, PROMIS, PFDI, PFIQ). She will also undergo a baseline POPQ exam and tests of physical function, including the 6-minute walk test and chair stand test.

A sealed envelope will then be opened by the research coordinator (or study investigator) in front of the patient indicating the patient's study allocation. The packet will also include an accelerometer which the patient will be instructed to wear for a 7-day period preoperatively. However, to ensure that participants are not given an accelerometer too far in advance from her surgery (as at times surgery may be scheduled remotely from the initial decision to proceed with surgery which would potentially result in too many accelerometers being out of circulation), the envelope containing study allocation and accelerometers may alternatively be provided at the preoperative "Surgical Workup" visit once the surgery is scheduled and at a date no greater than 3 weeks from the planned surgery. If a participant will be undergoing surgery at an interval greater than 1 week from the initial receipt of the accelerometer, she will only be required to wear the accelerometer for 1 week prior to the surgery. Patients will be given an opportunity to ask any questions regarding postoperative activity instructions to research personnel or nurses at the time of study enrollment and at any point prior to her surgery. Patients will be notified, prior to providing consent, that her primary surgeon will remain blinded as to her treatment allocation until completion of her study participation.

Any questions related to surgical recovery which arise preoperatively will be addressed by nurses and research personnel not involved in the patient's intraoperative decision-making. Postoperatively, fellow and attending surgeons will only be unblinded if necessary to address any acute postoperative issues. Patients will also be provided with a duplicate set of postoperative set of activity instructions on the day of her surgery upon discharge which will be entered in the patient's electronic chart by study personnel on the day of her surgery as a modification to the standard postoperative discharge instructions.

The patient will wear the activity tracker for 6 weeks postoperatively. At the 1-week postoperative time point, patient reminder phone calls will be made to remind the patient to wear and charge the activity tracker (whose battery life is 25 days). She will also be asked to provide a count of the number of narcotic pills she has left remaining at this time. She will follow-up for a routine postoperative visit with her primary surgeon at which point a routine 6-week postoperative POPQ will be performed. Accelerometers will be returned at this visit.

She will then follow up for a separate research visit at 3 months postoperatively. At this time, the patient will complete all follow-up activity, symptom, and HRQOL questionnaires including the: Activities Assessment Scale, Pelvic Floor Distress Inventory, Pelvic Floor Impact Questionnaire, and the PROMIS short form subscales of physical function, anxiety, depression, fatigue, satisfaction with social role, and pain interference. A six-minute walk and chair stand test will be administered by trained research personnel in the clinic. She will additionally be inquired regarding timing of return to work. A POPQ will also be performed at this time by a blinded provider NOT involved in the patient's index surgery.

Being tested
Expedited postoperative activity instructions, Standard postoperative activity restructions
Medical subject headings
Pelvic Organ Prolapse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Expedited postoperative activity instructionsBehavioural

    Ad lib postoperative activity and return to work recommendations

  • Standard postoperative activity restructionsBehavioural

    Standard conservative postoperative activity and return to work recommendations

Study groups in NCT04329715
Study groupRoleWhat they receive
Expedited instructionsExperimentalNot described
Receives: Behavioral: Expedited postoperative activity instructions
Restricted instructionsActive comparatorNot described
Receives: Behavioral: Standard postoperative activity restructions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum support loss "SLMax"

    Most distal point of pelvic organ support (in centimeters) based on Pelvic Organ Prolapse Quantification system

    Measured: 3 months

  2. Prolapse symptoms

    Pelvic Organ Prolapse Distress Inventory (POPDI) at 3 months

    Measured: 3 months

Secondary outcomes (11)
  1. Recovery time

    Time to resumption of >90% of baseline activity, measured with ActiGraph accelerometer worn pre- and 6 weeks postoperatively

    Measured: 6 weeks

  2. Health related quality of life (HRQOL)

    HRQOL as measured by the PROMIS short form subscales of physical function, anxiety, depression, fatigue, satisfaction with social role, and pain interference

    Measured: 3 months

  3. Physical function

    Functional aerobic capacity as measured by the 6 Minute Walk Test

    Measured: 3 months

  4. Physical function

    Functional strength as measured by the Chair Stand Test

    Measured: 3 months

  5. Time to return to work

    Postoperative day at which patient returned to work

    Measured: 3 months

  6. Postoperative opioid requirement

    Opioid pill count

    Measured: 2 weeks

  7. Pelvic floor symptom severity

    Measured by the Pelvic Floor Distress Inventory-20

    Measured: 3 months

  8. Pelvic floor symptom severity

    Measured by the Pelvic Floor Impact Questionnaire-7

    Measured: 3 months

  9. Functional activity

    As measured by the Activities Assessment Scale

    Measured: 3 months

  10. Patient satisfaction

    As measured by Patient Global Impression of Improvement

    Measured: 3 months

  11. Postoperative morbidity

    Postoperative morbidity following surgery

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2020
  2. Study start1 Jul 2020
  3. Primary completion15 Feb 2022
  4. Study completion15 Feb 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized controlled non-inferiority trial
Masking
Triple blind
Who is masked
Care provider, Investigator, Outcomes assessor
Enrolment
123 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04329715
Sponsor's protocol ID
Pro00104389
Acronym
EVeRLAST
Status last verified
Feb 2022
First submitted
30 Mar 2020
Last updated
8 Mar 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Brubaker L, Barber MD, Nygaard I, Nager CW, Varner E, Schaffer J, Visco A, Meikle S, Spino C; Pelvic Floor Disorders Network. Quantification of vaginal support: are continuous summary scores better than POPQ stage? Am J Obstet Gynecol. 2010 Nov;203(5):512.e1-6. doi: 10.1016/j.ajog.2010.06.071. Epub 2010 Aug 21.

    PubMed 20728072
  • Tomioka K, Iwamoto J, Saeki K, Okamoto N. Reliability and validity of the International Physical Activity Questionnaire (IPAQ) in elderly adults: the Fujiwara-kyo Study. J Epidemiol. 2011;21(6):459-65. doi: 10.2188/jea.je20110003. Epub 2011 Sep 24.

    PubMed 21946625
  • O'Shea M, Siddiqui NY, Truong T, Erkanli A, Barber MD. Standard Restrictions vs Expedited Activity After Pelvic Organ Prolapse Surgery: A Randomized Clinical Trial. JAMA Surg. 2023 Aug 1;158(8):797-805. doi: 10.1001/jamasurg.2023.1649.

    PubMed 37256578

Questions about this trial

What is this clinical trial studying?

A study testing Expedited postoperative activity instructions and Standard postoperative activity restructions in people with Pelvic Organ Prolapse, run by Duke University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum support loss "SLMax" (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04329715, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in